801-531-9168

PTO/SB/08B(10-01) . Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

some are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449A/PTO Complete if Known Application Number 09/517,898 INFORMATION DISCLOSURE Filing Date March 3, 2000 STATEMENT BY APPLICANT Vogels et al. First Named Inventor Group Art Unit 1632 (use as many sheets as necessary) **Examiner Name** Q. Li 2578-3982 2LIS Attorney Docket Number

	1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	İ
Examinor Initials	Cite No.1	(book, magazine, journal, scrial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
X-		Crystal et al., Transfer of Gene to Human: Early Lessons and Obstacles to Success, 1995, Science, Vol. 270, pp. 404-10.	
		Eck et al., Gene-Based Therapy, 1996 Goodman & Gilman's, pp. 77-101.	
		Gaff et al., Journal of Virology, 1996, pp. 2116-23, Vol. 70.	
		Guszman et al., FNAS, 1994, pp. 10732-36, Vol. 91,	
		Kaya et al., A single armino acid substitution results in a retipoblestorm protein defective in phosphotylation and oncoprotein binding, September 1990, Proc. Natl. Acad. Sci., pp. 6922-26, Vol. 87.	
2		Lunky et al., Journal of Virology, 1998, pp. 2022-32, Vol. 72.	
		Rudinger et al., Characteristica of the affino acids as components of a poptide hormone sequence, 1976, Poptide Hormones, pp. 1-7.	
*		Su, et al., A Genetically Modified Admoviral Vector Exhibits Bahanced Gene Transfer of Human Smooth Muscle Cells, Journal of Vascular Research 2001, pp. 471-78, Vol. 38.	•
8		Wickham et al., Increased In Vitro and In Vivo Gene Transfer by Adenovirus Vectors Containing Chimeric Fiber Protein, Nov. 1997, Journal of Virology, pp. 8221-29, Vol. 71, No. 11.	
<b>X</b> _]		Wilson et al., Adenovirus Vectors In the Development of Gene Therapy, 1999, Priedman, T od. CSHL Press, Cold Spring Harbor, New York.	

Examiner Date Signature Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not circulous is in conformance with MPEP 609. Draw line through circulous if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.